Login to Your Account

DBV stock up on peanut allergy data; firm files for offering on Nasdaq

By Cormac Sheridan
Staff Writer

Tuesday, September 23, 2014
DUBLIN – Shares in DBV Technologies SA gained more than 20 percent Tuesday on positive news from a phase IIb trial of the company's Viaskin Peanut allergy treatment.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription